MedWatch

Here are the strategies of Novo’s rivals

Two of Novo Nordisk’s fiercest rivals have very distinct strategies in the battle for control of the global diabetes market. Medwatch has spoken to key people from Sanofi and Eli Lilly.

Foto: Colourbox

Sanofi and Eli Lilly are at two different stages at the moment. In the drug Lantus, Sanofi has the world’s by far bestselling diabetes drug – in fact, with a sales increase of 1.4 billion dollars it was the global pharmaceutical industry’s fastest growing drug in 2012. Eli Lilly, on the other hand, is in the process of returning to the lead group after having fallen behind within diabetes in recent years.

But it is largely between these two companies and Danish Novo Nordisk that the war for control of the global diabetes market will be waged – a market that is estimated to grow to more than 500 billion kroner (USD 86 billion) within the next five years.

Læs hele artiklen

Få 14 dages fri adgang.

Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier